,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['biomarker', 'destiny04']
 the new her2 testing discussion among pathologists after #destiny04 trial #asco22 pointing out both the limits of ihc, as well as the promise for pts that we don't have a true biomarker right now to at least most be able to access t-dxd... 
Translational Medical Oncologist (Biomarkers, Toxicities, Health Outcomes, Clinico-Genomic Big Data) @OncoAlert. Motto: "Let's make a difference". Views mine.